石膏가 만성 신부전 Rat의 신기능 보호 및 조직학적 변화에 미치는 영향
The Effects of Gypsum Fibrosum on Renal Functional and Histopathological Disorder in Chronic Renal Failure Rat Model
1
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Objective : Gypsum fibrosum has been traditionally used in treatment of febrile diseases and recently been shown to have anti-inflammatory effect. Chronic renal failure has a serious clinical symptoms including proteinuria, azotemia, anemia, and hyperlipidemia and has characteristic histopathological changes, glomerular hypertrophy, infiltration of inflammatory cells, and crescentic sclerosis. We investigated the effects of gypsum fibrosum on renal functional and histopathological disorder in chronic renal failure rat model induced 5/6 nephrectomy. Methods : Using Sprague-Dawley rats, CRF was induced by 5/6 nephrectomy. The rats were divided into 3 groups, normal, conrol, and gypsum administered orally with gypsum fibrosum 500㎎/㎏/day. Body weight, 24 hr proteinuria, hematologic analysis, and histological morphologic changes were followed up after 8 weeks. The glomerular macrophage /monocyte infiltration, TGF-β1, type Ⅳ collagen, and angiotensin Ⅱ type1 receptor(AT1) were evaluated by immunohistochemistry. Resuls : In the CRF control group, functional parameters and histopathologic changes clearly indicated the development of CRF. 24 hr proteinuria significantly increased in the CRF control group over the normal group, and serum creatinine level was lower in the gypsum group than in the control group. LDL-cholesterol was significantly lower in the gypsum group than in the control group. Morphological investigations showed a variety of characteristic features of CRF, glomerular hypertrophy, increasing cellular density of glomerulus, deposition of extra-cellular matrix, fibrotic change, and glomerular sclerosis in the control group, but in the gypsum group, these features diminished significantly. In observation of renal type Ⅳ collagen and AT1 expression, positive area significantly increased in the control group over the normal group, and it significantly decreased in the gypsum group compared to the control group. Conclusions : Our findings suggest that gypsum fibrosum inhibits AT1 and type Ⅳ collagen expression in renal tissues and attenuates progression of glomerulosclerosis and interstitial fibrosis in chronic renal failure rats, which lead to amelioration of renal function. From these results, we suggest that gypsum fibrosum may have renoprotective effects and could be a useful remedy agent for treating chronic renal failure.
Abstract
Objective : Gypsum fibrosum has been traditionally used in treatment of febrile diseases and recently been shown to have anti-inflammatory effect. Chronic renal failure has a serious clinical symptoms including proteinuria, azotemia, anemia, and hyperlipidemia and has characteristic histopathological changes, glomerular hypertrophy, infiltration of inflammatory cells, and crescentic sclerosis. We investigated the effects of gypsum fibrosum on renal functional and histopathological disorder in chronic renal failure rat model induced 5/6 nephrectomy. Methods : Using Sprague-Dawley rats, CRF was induced by 5/6 nephrectomy. The rats were divided into 3 groups, normal, conrol, and gypsum administered orally with gypsum fibrosum 500㎎/㎏/day. Body weight, 24 hr proteinuria, hematologic analysis, and histological morphologic changes were followed up after 8 weeks. The glomerular macrophage /monocyte infiltration, TGF-β1, type Ⅳ collagen, and angiotensin Ⅱ type1 receptor(AT1) were evaluated by immunohistochemistry. Resuls : In the CRF control group, functional parameters and histopathologic changes clearly indicated the development of CRF. 24 hr proteinuria significantly increased in the CRF control group over the normal group, and serum creatinine level was lower in the gypsum group than in the control group. LDL-cholesterol was significantly lower in the gypsum group than in the control group. Morphological investigations showed a variety of characteristic features of CRF, glomerular hypertrophy, increasing cellular density of glomerulus, deposition of extra-cellular matrix, fibrotic change, and glomerular sclerosis in the control group, but in the gypsum group, these features diminished significantly. In observation of renal type Ⅳ collagen and AT1 expression, positive area significantly increased in the control group over the normal group, and it significantly decreased in the gypsum group compared to the control group. Conclusions : Our findings suggest that gypsum fibrosum inhibits AT1 and type Ⅳ collagen expression in renal tissues and attenuates progression of glomerulosclerosis and interstitial fibrosis in chronic renal failure rats, which lead to amelioration of renal function. From these results, we suggest that gypsum fibrosum may have renoprotective effects and could be a useful remedy agent for treating chronic renal failure.
참고문헌 (35)
- 杜鎬京, "東醫腎系學", pp.527~535 (1992), 東洋醫學硏究院
- 대한신장학회, "임상신장학", pp.593~600 (2001), 광문출판사
- 김현철, "임상 신장학", pp.195~218 (1997), 계명대학교 출판부
- 양지혜, "만성 요독 흰쥐에서 Hydroxychloroquine 투여에 의한 신 손상 억제 효과", The Korean Journal of Nephrology, 20(6), pp.964~974 (2001), 대한신장학회
- Byung-Cheol Lee, "The inhibitory effects of Magnolia Officinalis on human mesangial cell proliferation by regulation of PDGF-BB, TGF-β1 and CDK2 expression" (2004), Dep. of Oriental Internal Med.
- Christian F, "Suitability of 5", 6 nephrectomy for the induction of interstitial renal fibrosis in rats-Influence of sex, strain, and surgical procedure, 2006, pp.57, 195~205
- Yoshitaka I, "Glomeruloclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney", J. Clin. Invest, 92, pp.2597~2601 (1993)
- 楊東喜, "本草備要解析", pp.516~521 (1974), 國興出版社
- 李平, "中草藥腎損害與中醫藥治療", pp.359~360 (2003), 人民衛生出版社
- 조영삼, "백서에서 신부전 모델의 개발", 대한비뇨기과학회지, 45(6), pp.592~596 (2004), 대한비뇨기과학회
- 馬繼興, "神農本草經輯注", pp.300~302 (1995), 人民衛生出版社
- 凌一揆, "중약본초학", pp.202~203 (1998), 보건신문사
- 鄭虎占, "中藥現代硏究與應用", pp.5281~5293 (1999), 學苑出版社
- Anderson Ricardo Roman Goncalves, "Renal expression of COX-2, ANG Ⅱ, and AT1 receptor in remnant kidney:strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory", American Journal of Physiology, 286, pp.945~954 (2004)
- Makoto Mizuno, "The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes", Cardiovasc Pharmacol, 45, pp.135~142 (2006)
- Brites FD, "renal failure in diabetic patients increases lipid risk factors for atherosclerosis", Diabetes Res Clin Pract, pp.1~7 (2006)
- Chang Jun Yoon, "The effect of Externally Administered Insulin- like Groth factor-1 on Glomerulosclerosis during Compensatory Renal Hypertrophy in Rats", The Korea Urological Association, 42, pp.406~412 (2001)
- O. Viklicy, "TGF-β1 expression and chronic allograft nephropathy in protocol kidney graft biopsy", Physiol Res, 52, pp.353~360 (2003)
- Seiya O., "Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis", J. Clin. Invest, 86, pp.453~462 (1990)
- Shoji Kagami, "Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells", The American Societh for Clinical Investigation, 93, pp.2431~2437 (1994)
- Kyu Hun Choi, "The effects of high glucose concentration on angiotensin II-or transforming growth factor-β-induced DNA synthesis, hypertrophy and collagen synthesis in cultured rat mesangial cells", Yonsei Medical Journal, 37(5), pp.302~311 (1996)
- Eun-Jung Kim, "Angiotensin Ⅱ AT1 receptor blockade change expression of renal sodium transporter in rats with chronic renal failure", J Korean Med Sci, 20, pp.248~255 (2005)
- Jean Claude Aldigier, "Regression of existing glomerulosclerosis by inhibition of aldosterone", the American Society of Nephrology, 16, pp.3306~3314 (2005)
- Li-Jun Ma, "Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1", J Am Soc Nephrol, 16, pp.966~976 (2005)
- Rober H.Weiss, "TGF-β-and angiotensin-II induced mesangial matrix protein secretion is mediated by protein kinase C", Nephrology Dial Transplantation, 13, pp.2804~2813 (1998)
- O. Viklicky, "TGF-β1 Expression and Chronic Allograft Nephropathy in Protocol Kidney Graft Biopsy", Physiological reaserch, 52, pp.353~360 (2006)
- Beltrame Ribeiro, "Angiotensin II antagonists- Clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria", Arq Bras Endocrinol Metab, 50, pp.327~333 (2006)
- Maki Shimizu, "Role of intergrin-linked kinase in epithelial- mesenchymal trasition in crescent formation of experimental glomerulonephritis", NDP, 21, pp.2380~2390 (2006)
- Yee-Young Na, "Glomerular epithelial-myofibroblast transdifferentiation in the evolution of glomerular crescent formation", Nephrology Dial Transplantation, 14, pp.2860~2872 (1999)
- Yoshihide Fujigaki, "Cytokines and cell cycle regulation in the fibrous progression of crescent formation in antiglomerular basement membrane nephritis of WKY rats", Virchows Arch, 439, pp.35~45 (2001)
- Wong Kok Seng, "Losartan reduces the costs of diabetic end-stage renal disease: An Asian perspective", NEPHROLOGY, 10, pp.520~524 (2005)
- Dimitrios S.Goumenos, "Urinary transforming growth factor-beta I as a marker of response to immunosuppressive treatment, in patients with crescentic nephritis", BMC Nephrology, 6(16), pp.1~7 (2005)
- Luis M.Ruilope, "Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus", A review of the clinical trial evidence, 25(12), pp.3044~3064 (2003)
- Makoto Mizuno, "Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes", Hypertens Res, 25(2), pp.271~278 (2002)
- Yukiko Nagai, "Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats", J Am Soc Nephrol, 16, pp.703~711 (2005)